SGLT2 Inhibitor Guideline Recommendations for Chronic Kidney Disease, Heart Failure, and Type 2 Diabetes
Chronic Kidney Disease (CKD)
Strong recommendation to use SGLT2 inhibitors in adults at high risk (eGFR 30‑44 mL/min/1.73 m² with albuminuria ≥ 200 mg/g) or very high risk (eGFR < 30 mL/min/1.73 m² with albuminuria ≥ 200 mg/g) of CKD progression, irrespective of diabetes status. Strength: strong recommendation. 1
Weak recommendation for adults at moderate risk (eGFR 45‑59 mL/min/1.73 m² with albuminuria 30‑200 mg/g) and for low‑risk patients. Strength: weak recommendation. 2
In very high‑risk patients, SGLT2 inhibitor therapy yields 48 fewer deaths and 58 fewer kidney‑failure events per 1,000 patients over 5 years (high‑certainty evidence). 1
The recommendation applies to all adults with CKD, whether or not they have type 2 diabetes. 3
Heart Failure
Mandatory therapy with an SGLT2 inhibitor for all adults with heart failure (both reduced and preserved ejection fraction), regardless of diabetes status or HbA1c level. 4
Treatment reduces the composite outcome of cardiovascular death or heart‑failure hospitalization by 26‑29 % when added to optimal background heart‑failure therapy. 4
Type 2 Diabetes Mellitus (T2DM)
For patients on metformin with HbA1c ≥ 7 %, adding an SGLT2 inhibitor lowers all‑cause mortality, major adverse cardiovascular events, CKD progression, and heart‑failure hospitalizations. 4
Priority indication for patients who have established cardiovascular disease, heart failure, or CKD (eGFR 20‑60 mL/min/1.73 m² and/or albuminuria ≥ 200 mg/g). [4][5]
Consider SGLT2 inhibitor therapy in individuals with metabolic‑dysfunction‑associated steatotic liver disease (MASLD) and overweight/obesity. 4
Contraindications & Special Populations
Not recommended for patients with polycystic kidney disease or those requiring immunosuppressive therapy for kidney disease. 5
Not recommended for kidney‑transplant recipients because of limited data and a potential increase in infection risk. 5
Dosing for Cardiovascular/Renal Protection
Recommended dose: 10 mg orally once daily for all indications except when the goal is solely glycaemic control. [6][4]5
Therapy may be initiated when eGFR ≥ 20 mL/min/1.73 m² (some guidelines accept ≥ 25 mL/min/1.73 m²). [6][4]5
Continue the drug even if eGFR falls below 20 mL/min/1.73 m² during treatment, unless the patient cannot tolerate it or requires kidney‑replacement therapy. 5
Renal Thresholds for Different Indications
Discontinue SGLT2 inhibitor for glucose‑lowering purposes when eGFR < 45 mL/min/1.73 m² (efficacy markedly reduced). [6][4]
For cardiovascular or renal protection, maintain therapy down to eGFR 20 mL/min/1.73 m² in patients with compelling indications. [6][5]
Monitoring Requirements
Before initiation: assess renal function (eGFR and urine albumin‑to‑creatinine ratio). 5
Baseline volume assessment and correction of volume depletion, especially in older adults (≥ 75 years), those on diuretics, or with low systolic blood pressure. 4
During treatment: monitor eGFR every 3‑6 months if baseline eGFR < 60 mL/min/1.73 m², and annually if ≥ 60 mL/min/1.73 m². 5
Expect an initial reversible eGFR decline of 3‑5 mL/min/1.73 m²; this should not prompt discontinuation. 5
Genital mycotic infections occur in ~6 % of treated patients versus ~1 % with placebo; monitor for these and for urinary‑tract infections. 4
Safety monitoring: watch for signs of volume depletion. [4][5]
Combination Therapy & Alternatives
Renin‑angiotensin system inhibitors (ACEi or ARB) can be used together with SGLT2 inhibitors for additive kidney protection. 5
Non‑steroidal mineralocorticoid receptor antagonists may be added when albuminuria persists despite optimal SGLT2 inhibitor and RASi therapy. 5
GLP‑1 receptor agonists are an alternative for CKD patients with eGFR 20‑60 mL/min/1.73 m² and/or albuminuria, especially when additional weight‑loss or cardiovascular benefit is desired. 4
Metformin remains the first‑line oral agent for type 2 diabetes; SGLT2 inhibitors are added when glycaemic targets are not met. 4
Evidence‑Based Recommendations for SGLT2 Inhibitor Use and Dosing
Cardiovascular and Renal Outcomes
- SGLT2 inhibitors reduce cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. (American College of Cardiology, 2018) 7
Dosing Recommendations by Agent
Empagliflozin
- Standard dose for cardiovascular/renal protection is 10 mg once daily; a higher 25 mg dose may be used when additional glycemic control is needed. (American College of Cardiology, 2018) 7
Canagliflozin
- Initial dose is 100 mg once daily taken before the first meal; the dose may be increased to 300 mg daily when eGFR ≥ 60 mL/min/1.73 m² and further glycemic lowering is required. (American College of Cardiology, 2018; Mayo Clinic, 2022) 7, 8
Dapagliflozin
- Begin with 5 mg once daily; titrate to 10 mg daily if additional glycemic control is needed. For all cardiovascular and renal indications (except sole glycemic use), the recommended dose is 10 mg daily. (Mayo Clinic, 2022) 8
eGFR‑Based Dosing Adjustments
Glycemic‑Control Indications
- Empagliflozin – Initiate only if eGFR ≥ 45 mL/min/1.73 m²; discontinue if eGFR persistently falls below 45 mL/min/1.73 m². (American College of Cardiology, 2018) 7
- Canagliflozin – No dose adjustment when eGFR ≥ 60 mL/min/1.73 m²; limit to 100 mg daily when eGFR is 45–59 mL/min/1.73 m²; not recommended for glucose‑lowering when eGFR < 45 mL/min/1.73 m². (American College of Cardiology, 2018; Mayo Clinic, 2022) 7, 8
- Dapagliflozin – No dose adjustment when eGFR ≥ 45 mL/min/1.73 m²; not recommended for glucose‑lowering when eGFR < 45 mL/min/1.73 m². (Mayo Clinic, 2022) 8
Cardiovascular/Renal‑Protection Indications (Canagliflozin for CKD)
- Canagliflozin dosing for chronic kidney disease – No adjustment when eGFR ≥ 60 mL/min/1.73 m²; 100 mg daily when eGFR is 30–59 mL/min/1.73 m²; 100 mg daily also when eGFR < 30 mL/min/1.73 m² and albuminuria > 300 mg/day; initiation not recommended when eGFR < 30 mL/min/1.73 m² without albuminuria. (Mayo Clinic, 2022) 8